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Abstract: Infliximab is a monoclonal antibody against tumor necrosis factor (TNF) which has 
become an established therapy for Crohn’s disease over the last 10 years. Given the similarities 
between Crohn’s disease and ulcerative colitis (UC), it is no surprise that gastroenterologists 
have used infliximab in patients with UC who have failed other therapies. Although the initial 
controlled trials with infliximab in steroid-refractory disease were unimpressive, subsequent 
controlled trials have demonstrated the efficacy of infliximab in both moderate to severe disease, 
and as rescue-therapy to avoid colectomy. The long-term remission rates, colectomy-sparing 
effects, and the impact of concomitant immunomodulator therapy, remain to be determined in 
these patients. Whether infliximab is a superior strategy to cyclosporine in patients with steroid-
refractory disease is controversial. This review examines the data on the efficacy and safety of 
infliximab as an induction and maintenance agent for UC.
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Introduction
Ulcerative colitis (UC) is a chronic idiopathic inflammatory disease of the colon. The 
characteristic phenotype typically involves only the colon, though extra-intestinal 
manifestations may occur, affecting the joints, liver, eyes and skin. UC shares the 
umbrella term “inflammatory bowel disease” (IBD) with Crohn’s disease, though their 
phenotypes differ substantially, particularly as Crohn’s disease can affect any part of 
the gastrointestinal tract. The prevalence of UC varies worldwide, though retrospec-
tive studies suggest that it is more common in Northern Europe, the UK, and North 
America.1,2 However, there are reports of increasing incidence and prevalence in south 
and central Europe, Asia, Africa, and Latin America.1,3 In the US, the prevalence among 
adults ranges from 37 to 246 per 100,000 population.4 Similarly, European prevalence 
rates vary widely, ranging from 21 to 243 per 100,000 population.1
Though UC can occur at any age, it typically presents in youth, between 15 and 
35 years, with a second peak incidence in the 55- to 65-year-old age group.5 The typi-
cal symptoms of UC include rectal bleeding, abdominal pain, diarrhea, weight loss, 
and growth failure. Less common symptoms include joint pain, dry eyes and rashes. 
These symptoms can be exacerbated by antibiotic use, cessation of smoking, use of 
NSAIDs, and psychological stress.
The etiology of UC is unclear, but our current understanding is that an environ-
mental trigger in susceptible individuals leads to dysregulated inflammation and tissue 
damage.6Clinical and Experimental Gastroenterology 2009:2 150
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The environmental trigger has yet to be defined, and there 
does not appear to be a single dominant pathogenic gene that 
increases susceptibility to UC. Genome-wide association 
studies have implicated susceptibility regions on at least 12 
chromosomes to date.7
Once an inflammatory cascade has been elicited, both 
macrophages and T-lymphocytes play a role in propagating 
tissue damage in the intestinal mucosa. T cell activation in UC 
has historically appeared to be initiated with a predominantly 
T-helper-2 (Th2) cytokine profile, maintained by interleukin-12 
(IL-12) activity.7 This leads to inflammatory cytokine release, 
including IL-5 and IL-13, and appears to indirectly stimulate 
macrophages to release tumor necrosis factor (TNF) and IL-1 
and IL-6, which further drive the inflammatory cascade. This 
can be contrasted to Crohn’s disease, which has a cytokine 
profile more associated with T-helper-1 (Th1) cells.
Recently, the emergence of a more complex framework 
of T-helper cell activity has led to the recognition of a role 
for T-helper-17 (Th17) cells, derived from a lineage separate 
to that of Th1 and Th2 cells. Activation and maintenance 
of these cells, driven by IL-23 (of the IL-12 family) leads 
to heightened IL-17 production.8 This IL-23/IL-17 axis 
of inflammation appears to be an important component in 
intestinal inflammation in IBD;9 animal models of colitis, 
and human studies of patients with active UC, have reported 
a higher proportion of TH17-producing IL-17 cells in the 
inflamed mucosa.10–12 Of note, inhibition of TNF significantly 
decreased expression of IL-23 and IL-17 in an animal model 
of colitis, suggesting TNF remains an intricate component 
of the IL-17/IL-23 pathway also.13
The traditional therapeutic strategies for UC target 
these inflammatory pathways to induce a clinical response 
and/or maintain disease remission.14 Drugs that release 
5-aminosalicylic acid (5-ASA) (mesalazine, sulphasalazine, 
olsalazine, balsalazide) have topical anti-inflammatory effects 
in the colon, and can be administered orally or rectally. They 
have proven efficacy in both the induction and maintenance 
of remission of UC. In patients with more severe disease, 
steroids (prednisone, hydrocortisone) or cyclosporine have 
been used to induce remission of disease. Immunomodula-
tors, such as azathioprine or 6-mercaptopurine (6-MP), have 
typically been used to maintain the remission induced by 
steroids or cyclosporine, or in patients who are intolerant of 
5-ASAs. Occasionally, patients with severe UC fail medical 
therapy, and need a colectomy.
The agents discussed above exert their anti-inflammatory 
action by broad, nonspecific effects on immune cell func-
tion, with often poorly understood mechanisms of action. 
The development of infliximab led to the emergence of 
cytokine-specific agents with a more defined target, in this 
case TNF and TNF-bearing cells.
Rationale for the use of anti-tumor 
necrosis factor (anti-TNF) in UC
TNF was first described in 197515 and named for its ability 
to lyse tumors in vitro and in mouse models. It is a cytokine 
that is initially membrane-bound (mTNF) on its source cells, 
but released as soluble TNF (sTNF) after enzymatic cleavage 
by TNF converting enzyme (TACE). TNF is produced by 
activated macrophages and T cells in areas of inflammation, 
and plays a role in the pathogenesis of UC. As a ligand it has 
a number of biological effects in inflammatory states:16
•  neutrophil migration to the inflamed colon
•  activation of CD4+ lymphocytes
•  activation of matrix metalloproteinases
•  weakening of cellular tight junctions
•  inhibition of apoptosis of T-cells
Increased concentrations of TNF have been reported in 
the blood, colonic tissue and stool of patients with UC.17–19 
Upregulation of TNF converting enzyme (TACE) has also 
been demonstrated in UC, which is important for conversion 
of mTNF to sTNF.20 TNF has thus a critical role in local-
ized and systemic inflammatory reactions, and inhibition of 
TNF activity would be expected to have anti-inflammatory 
benefits.
Pharmacology of infliximab
Development
Anti-TNF antibodies were first manufactured in the 1990s21 
and infliximab (Remicade®; Centocor, Malvern, PA, USA 
became the first commercially available form. It is a chime-
ric) antibody to TNF (human IgG1 coupled to the variable 
regions of mouse anti-TNF), with a high affinity to the soluble 
and trans-membrane forms of TNF, thus binding both forms 
of this cytokine.22 Infliximab was approved for use by the 
Food and Drug Administration (FDA) in moderate to severe 
fistulizing Crohn’s disease in October 1998,23 and a year later 
in rheumatoid arthritis (RA) (November 1999).24 Its license 
has since been extended for use in ankylosing spondylitis, 
plaque psoriasis and psoriatic arthropathy.25 Off-label uses 
include Behçet’s syndrome, uveitis, erythrodermic psoriasis, 
and pyoderma gangrenosum. Finally, in October 2006, inflix-
imab was the first anti-TNF antibody to be licensed for use 
in the treatment of moderate to severe UC.26 The European 
Medicines Agency (EMEA) approved infliximab for the treat-
ment of severe or fistulizing Crohn’s disease in August 1999, Clinical and Experimental Gastroenterology 2009:2 151
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and for RA in June 2000.27 Licensure for use of infliximab 
in severe UC occurred in October 2006.28
Pharmacokinetics
Infliximab binds specifically to human TNF-α with an asso-
ciation constant of 1010/M.29 After intravenous (iv) infusion 
of 5 mg/kg, the Cmax is 118 µg/mL, and infliximab is cleared 
from the circulation at a rate of 10 mL/h. By week 12 after 
infusion, infliximab levels are near undetectable (median 
concentration 0.1 µg/mL) with the 5 mg/kg dose but a 
dose of 10 mg/kg iv maintained therapeutic concentrations 
for a longer period. The volume of distribution of infliximab 
is 3 to 6 L, and serum levels decline slowly in a linear manner, 
leading to an elimination half-life of 7 to 12 days.25,30
Repeated doses of infliximab do not appear to result in 
accumulation; in one study in which Crohn’s patients were 
receiving 10 mg/kg infusions and had blood taken prior to 
each infusion, median serum infliximab concentrations were 
7.9, 10.0, 8.1, and 8.0 g/mL at weeks 20, 28, 36 and 44, 
respectively.31 Recommended dosing for UC reflects that for 
Crohn’s disease; 5 mg/kg iv over 2 hours at 0, 2 and 6 weeks, 
followed by 5 mg/kg iv maintenance therapy every 8 weeks 
thereafter. If patients prove refractory, dose may be increased 
to 10 mg/kg at the regimen above, or 5 mg/kg doses may be 
given as maintenance at 6-weekly intervals, a strategy that 
has been used in Crohn’s disease to overcome antibodies to 
infliximab (ATIs).32,33
Mechanisms of action
At a molecular level, infliximab was initially thought simply to 
bind to soluble TNF and thus neutralize its pro-inflammatory 
effects. Subsequent experiments in humans and in vitro have 
demonstrated that anti-TNF antibodies can:
•  induce apoptosis in monocytes and lymphocytes by 
binding membrane-bound TNF34,35
•  decrease in vitro production of TNF and IFN-γ by 
intestinal/peripheral blood T cells36
•  disrupt CD40/CD40L pathways in peripheral blood 
lymphocytes37
•  inhibit granulocyte-macrophage colony stimulating factor 
production by T-lymphocytes38
•  restore the gut barrier in patients with Crohn’s disease39
•  inhibit integrin expression on the endothelium40
Technetium-labeled infliximab studies have demon-
strated no or minimal uptake of infliximab in the intestine 
up to 20 hours after infusion, suggesting that its initial main 
location of action is in the blood stream.41 Complementary 
to this, many molecular events begin early after infusion of 
infliximab; C-reactive protein and IL-1β levels fall within 
hours, and whole blood levels of TNF drop significantly 
within 24 hours of infusion.42
Recent in vitro data have demonstrated that infliximab 
neutralizes both membrane and soluble TNF, inhibits 
IL-1β release from monocytes, and induces cytotoxicity 
and apoptosis.43 TNF neutralization per se may not be the 
main mechanism of action in IBD, as the recombinant 
human soluble TNF receptor etanercept was not efficacious 
in Crohn’s disease in a clinical trial,44 despite the fact that 
it binds to both mTNF and sTNF, and induces apoptosis.45 
Thus, the mechanisms through which infliximab mediates 
its anti-inflammatory effects in UC are multi-factorial. 
It has been proposed that reverse signaling through the TNF 
receptor may play a role.46 Infliximab can bind mTNF, and 
mTNF can activate NFkB pathways in leukocytes.47 Almost 
all these data comes from animal models, or samples from 
patients with Crohn’s disease, although it is assumed the 
mechanisms are relevant to UC.
Clinical trials of infliximab in UC
Evidence for the efficacy of infliximab in UC comes from 
a series of open-label studies, randomized controlled trials 
(RCTs), and meta-analyses. The outcomes seen with inflix-
imab in these trials can be considered to be typical patient 
populations seen in clinical practice; moderate to severe 
UC, steroid-refractory UC, and cyclosporine-refractory UC. 
Cyclosporine is also a valid therapy in some of these cohorts, 
and will be discussed below (Alternatives to infliximab).
Evidence from randomized  
controlled trials
Table 1 lists randomized trials in which response to inflix-
imab is assessed with various endpoints such as clinical 
response, remission and colectomy rates. In patients with 
severe, steroid-refractory UC, the initial small trials dem-
onstrated modest efficacy after single infusions when early 
clinical response was determined. The first published trial 
by Sands et al48 in 2001 randomized 11 patients with steroid 
refractory UC to a single infliximab infusion or placebo, and 
noted a 50% (4/8) clinical response rate with infliximab at 
a week 2 evaluation (a further patient in the 20 mg/kg arm 
went into clinical remission by week 6). Subsequent studies 
by Probert et al49 and Jarnerot et al50 also enrolled patients 
with steroid-refractory disease. Probert et al failed to show 
any significant difference between placebo and 2 infusions 
of infliximab 5 mg/kg in endoscopic improvement or clinical 
remission. However, Jarnerot et al demonstrated in patients Clinical and Experimental Gastroenterology 2009:2 152
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with moderate and severe steroid-refractory UC that only 
7/24 (29%) patients who received a single infliximab infusion 
underwent colectomy within 90 days (and indeed 6 months), 
compared with 14/21 (67%) who received placebo. The 
superiority of infliximab was only statistically significant in 
patients with moderate to severe disease (by Seo score), not in 
those with more severe disease on the fulminant colitis score, 
although the study was not powered to detect differences 
between these groups. At 2 years follow-up, the colectomy 
rate in patients who received infliximab had increased to 
46%.51 These studies positioned infliximab as a therapeutic 
option for patients with steroid-refractory disease.
Initial controlled trials52,53 of patients who had moderate 
to severe disease only reported superior clinical response 
rates to those seen in steroid-refractory populations. These 
trials reported high response rates (100%, 83% respectively), 
but follow-up was short (9.7, 3 months, respectively). The 
ACT 1 and ACT 2 trials54 each randomized 364 patients 
with moderate to severe UC who were failing conventional 
therapy(but did not require admission) to either placebo, 
or induction/maintenance infliximab 5 mg/kg or 10 mg/kg. 
Eligible patients had moderate to severe UC despite concur-
rent treatment with corticosteroids alone or in combination 
with azathioprine or mercaptopurine in both ACT 1 and 
ACT 2 – ACT 2 also required that the patient failed 5-ASA 
therapy. In ACT 1, both doses of infliximab (5 mg/kg and 
10 mg/kg) resulted in a statistically significant clinical 
response at week 8 (68.4% and 61.5% respectively, 
P  0.01, compared to a placebo response of 37.2%). This 
was similar in ACT 2, with clinical response at week 8 of 
64.5% in the infliximab 5 mg/kg group and 69.2% in the 
infliximab 10 mg/kg group, compared to a 29.3% response 
rate in the placebo group (P  0.001). Clinical remission rates 
in the infliximab arms at week 8 ranged from 27.5% to 38.8% 
across both studies compared to placebo-induced remission 
rates of 14.9% (ACT 1) and 5.7% (ACT 2). Mucosal heal-
ing and steroid-free remission rates were also superior in the 
infliximab arms of these studies. Colectomy rates in patients 
in ACT 1 and ACT 2 were reported in a follow-up study by 
Sandborn et al.55 The cumulative colectomy rate at 54 weeks 
was 10% in patients treated with infliximab, compared with 
17% in those treated with placebo. These colectomy rates 
were not unexpected given the enrolled patients had moderate 
to severe disease, although there was incomplete colectomy 
follow-up data in 13% of the enrolled patients.
The ACT 1 and ACT 2 studies were well-designed, large 
studies, with comprehensive assessment of clinical and sec-
ondary endpoints. They provide important data to support the 
use of infliximab in patients with moderate to severe UC who 
have failed other therapies such as steroids, immunomodula-
tors and mesalamine. However, infliximab is not a panacea 
for all; the proportion of patients who started the study on 
steroids, and were able to come off and remain in remission, 
was low (20%). This is comparable to the results in Crohn’s 
disease with other anti-TNFs.56
Uncontrolled studies
A number of open label (and mostly retrospective) studies 
have been performed within the past 8 years, and though 
many have added weight to the above findings, some reports 
have been conflicting (see Table 2). Initial studies57–62 mainly 
involved patients with steroid-refractory UC, and reported 
Table 1 Data from randomized trials investigating response and remission rates for infliximab in patients with ulcerative colitis
Author Year N Population Clinical 
response (%)a 
within 8 weeks
Clinical 
remission (%)a 
within 8 weeks
Colectomy Median 
follow-up
Sandborn et al55,b 2009 728 M-S and Sr n/a n/a 46/484 (10%) 54 weeks
rutgeerts et al54 (ACT 1) 2005 364 M-S and Sr 159/243 (65%) 86/243 (35%) 54 weeks
rutgeerts et al54 (ACT 2) 2005 364 M-S and Sr 161/241 (67%) 74/241 (31%) 30 weeks
Jarnerot et al50 2005 45 Sr n/a n/a 07/24 (29%) 6 months
Probert et al49 2003 43 Sr 13/23 (57%)c 09/23 (39%) 0/23 (0%) 2 months
Sands et al48 2001 11 Sr 5/8 (63%)d 2/8 (25%) 3/8 (37.5%) 3 months
Armuzzi et al52 2004 20 M-S 10/10 (100%) 10/10 (100%) 0/10 (0%) 9.7 months
Ochsenkuhn et al53 2004 13 M-S 05/06 (83%) 03/06 (50%) 0/6 (0%) 3 months
aNote definitions of clinical response and remission varied between groups.
bThese patients represent 728 patients evaluated in ACT 1 and ACT 2.54
cThese data represent endoscopic evidence of improvement, not clinical response.
d4/8(50%) patients achieved clinical response at week 2 evaluation; one further patient achieved clinical remission at week 6.
Abbreviations: M-S, moderate to severe ulcerative colitis; Sr, steroid refractory.Clinical and Experimental Gastroenterology 2009:2 153
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response rates of 50% to 100%, and early remission rates of 
20% to 100%. Colectomy rates varied greatly, ranging from 
0% to 63%, though differences in duration of follow-up, and 
patient populations included, can explain these differences.
Larger cohorts of patients were reported in studies involv-
ing patients who were both steroid-refractory and steroid-
dependent.63–65 Response rates ranged from 67% to 100%, 
with early remission rates of 40% to 66%, somewhat similar 
to smaller studies of steroid-refractory UC. Again, colectomy 
rates differed, ranging from 11% to 60% with equally differ-
ing duration follow-up. A review of the uncontrolled studies 
with higher cumulative colectomy rates appear to include 
patients with more severe disease; criteria such as “severely 
ill” (Aratari)62 and “candidate for colectomy” (Yamamoto-
Furusho)61 were used to select patients for infliximab in 
these studies.
As infliximab use became more common for severe UC, 
one clinical question that arose was its efficacy in patients 
with severe UC who had failed cyclosporine. Two small 
uncontrolled studies have addressed this issue.66,67 Though 
numbers were small, response rates of 60% and 81% were 
achieved, with early remission rates of 40% and 77%, respec-
tively. Considering these were patients who were likely to 
require colectomy soon, a colectomy rate of 40% and 38% 
in each study is lower than might be expected (follow-up 
7.8 and 6.5 months respectively). The point to note in this 
scenario is the high rate of infectious complications in 
patients in these studies who have been treated with multiple 
immunosuppressants.66
Meta-analyses
Reflecting these findings, a meta-analysis by Gisbert et al68 
combined 34 studies (896 patients) of patients with severe 
acute UC and found response and remission rates of 68% and 
40%, respectively, in the short term (median = 2.3 weeks), 
whereas in the long term (8.9 months) response and remission 
were found to be 53% and 39% respectively – all showed 
advantage of infliximab over placebo (P  0.001) in all 
endpoints. Rahimi et al69 in 2007 published data combining 
the results of 4 studies which showed a statistically significant 
summary odds ratio (OR) for clinical remission of 3.24 with 
a 95% confidence interval (CI) of 1.6 to 6.57. The summary 
OR for clinical response in 3 studies was 3.93 with a 95% 
CI of 2.84 to 5.45, again significant. Overall, infliximab was 
found to be effective in inducing response and remission in 
patients with UC when administered with corticosteroids. 
Finally, Lawson et al70 performed a Cochrane database review 
of randomized trials in which infliximab was used to treat UC 
refractory to conventional therapies. Seven such trials were 
selected, and infliximab was noted to be more effective than 
placebo in producing clinical remission (relative risk [RR] 
3.22, 95% CI 2.18 to 4.76), inducing endoscopic remission 
(RR 1.88, 95% CI 1.54 to 2.28) and in inducing clinical 
response (RR 1.99, 95% CI 1.65 to 2.41) at 8 weeks.
Table 2 Data from open label studies investigating the effect of infliximab in patients with ulcerative colitis
Author Year N Population Clinical 
response (%)a 
within 8 weeks
Clinical 
remission (%)a 
within 8 weeks
Colectomy Median 
follow-up
Gonzalez-Lama et al64 2008 47 M-S and Sr 47/47 (100%) 31/47 (66%) 05/47 (11%) 8.2 months
willert et al65 2008 15 M-S and Sr 13/15 (87%) 06/15 (40%) 09/15 (60%) 26 months
Su et al63 2002 27 M-S and Sr 18/27 (67%) 12/27 (44%) 05/27 (19%) 4 months
Aratari et al62 2008 11 Sr 11/11 (100%) 02/11 (18%) 24 months
Yamamoto-Furusho et al61 2008 10 Sr 08/10 (80%) 02/10 (20%) 08/10 (80%) 12 months
Kohn et al60 2004 13 Sr 10/13 (77%) 10/13 (77%) 03/13 (23%) 25.6 months
Actis et al59 2002 8 Sr 04/08 (50%) 04/08 (50%) 05/08 (63%) 7 months
Kaser et al57 2001 6 Sr 06/06 (100%) 04/06 (67%) 00/06 (0%) 5.5 months
Chey et al58 2001 8 Sr 08/08 (100%) 08/08 (100%) 00/08 (0%) 2.3 months
Jakobovits et al123 2007 30 Sr and Cr 05/30 (17%) 16/30 (53%) 13 months
Bermejo et al124 2004 7 M-S and Sr and Cr 06/07 (86%) 06/07 (86%) 00/07 (0%) 6 months
Gornet et al125 2003 28 M-S and Sr and Cr 16/18 (89%) 09/18 (50%) 10 months
Manosa et al67 2009 16 Cr 13/16 (81%) 10/13 (77%) 06/16 (38%) 6.5 months
Maser et al66 2008 10 Cr 06/10 (60%) 04/10 (40%) 04/10 (40%) 7.8 months
Note: aDefinitions of clinical response and remission varied between groups.
Abbreviations: Cr, cyclosporine refractory; M-S, moderate to severe ulcerative colitis; Sr, steroid refractory.Clinical and Experimental Gastroenterology 2009:2 154
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Safety of infliximab
The safety profile of infliximab has been established from 
a combination of case reports, postmarketing surveillance, 
and case-control studies, predominantly in patients with 
Crohn’s disease, but also from the clinical trials of UC. The 
most common adverse events reported relate to transient 
infusion reaction, but more serious events such as infections 
and cancer have been described. It should be noted that most 
of the safety data come from studies on Crohn’s disease and 
RA, in which concomitant immunosuppressives are used with 
infliximab, such as azathioprine, 6-MP or methotrexate. This 
can make it difficult to interpret which agent is contributing 
to adverse events.
infusion reactions
Infusion reactions are the most common adverse event of 
the drug, and can manifest rarely as a true allergic reaction, 
or more commonly as non-specific mild infusion reactions 
that are classified as anaphylactoid (nonallergic), non-IgE 
mediated reactions.71 Overall infusion reactions occurred 
in 10% and 18% of patients on infliximab in 2 studies.72,73 
Episodic therapy (episodic therapy involves giving infliximab 
as required, rather than regular maintenance infusions) has 
been associated with a higher risk of infusion reactions than 
regular maintenance therapy, presumably due to antibody 
formation between infusions.72
In ACT 1,54 infusion reactions occurred in 13 patients 
(10.7%) in the placebo group, 12 (9.9%) of the 5 mg/kg 
infliximab group, and 15 (12.3%) of the 10 mg/kg infliximab 
group (no significant difference between infliximab and 
placebo). Similar numbers of events between placebo and 
infliximab groups also occurred in ACT 2.
infections
Because TNF is involved in the immune system’s response 
to infection, there were initial concerns and case reports that 
infliximab could increase susceptibility to serious infec-
tions. The large infliximab registry reported by Lichenstein 
et al74 the TREAT registry, prospectively enrolled 6290 
Crohn’s patients, 3179 of whom were on infliximab (5519 
patient-years). Mean follow-up was of 1.9 years. Serious 
infections occurred more commonly in infliximab-treated 
patients than placebo (1.37 per 100 patient-years vs 0.65 
per 100 patient-years). However, infliximab patients were 
inherently sicker, with a more severe disease course, had 
more hospitalizations, and more surgeries. Thus, after 
multivariate analysis logistic regression, infliximab was not 
seen to be an independent risk factor of serious infection 
(odds ratio [OR] 0.99). Rather, prednisolone use was noted 
to be an independent risk factor for serious infection (OR 
2.21). One meta-analysis75 of randomized clinical trials of 
infliximab and adalimumab that included 3493 patients 
with RA revealed a pooled OR for serious infection of 
2.0 (patients taking anti-TNF group were twice as likely 
to develop serious infection compared to patients who 
were not on anti-TNF). Of the 126 serious infections, 
12 were granulomatous (10 cases of tuberculosis [TB], 
1 histoplasmosis and 1 coccidiomycosis).
The most widely discussed infection is reactivation of 
latent TB. One study from the AERS (FDA Adverse Event 
Reporting System)76 examined all reports of TB worldwide 
in patients on infliximab. Of the approx 147,000 patients 
who had been on the drug to date, there were 70 reported 
cases. Countries of high incidence were not over-represented. 
Interestingly, there was an unusually high likelihood of the 
extra-pulmonary manifestations of TB among infliximab-
treated patients. Otherwise, most infections attributed to 
infliximab are common bacterial infections. There have also 
been notable increases in the incidence of listeriosis77 and 
hepatitis B.78
In September 2008 the FDA released a statement to notify 
healthcare professionals regarding an increased risk in the 
development of invasive fungal infections such as histo-
plasmosis, coccidiomycosis, and blastomycosis.79 In ACT 1 
and ACT 2,54 the incidence of infections was similar among 
all groups (ranging 2% to 4.5%), and included one patient 
who developed tuberculosis (on infliximab 10 mg/kg) and 
another who developed histoplasma pneumonia (5 mg/kg 
infliximab).
Malignancy
The first concerns of malignancy driven by anti-TNF were 
discussed in a case series published in 200280 of 26 cases 
of lymphoproliferative disorders following treatment with 
etanercept or infliximab. Bongartz et al75 published a large 
meta-analysis of trials involving infliximab and adalim-
umab in RA and noted a pooled OR for malignancy of 
3.3 (95% CI 1.2 to 9.1). With this in mind, other studies have 
failed to prove a direct relationship between anti-TNF and 
malignancy. One such study in patients with RA81 found an 
equally increased risk of malignancy among RA patients 
taking and not taking anti-TNF therapies, suggesting rather 
that the underlying disorder or concomitant therapies may 
be driving malignant transformation.
Siegel et al82 published data on a meta-analysis comparing 
Crohn’s patients on anti-TNF to population (SEER) data Clinical and Experimental Gastroenterology 2009:2 155
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and Crohn’s patients on thiopurine immunosuppressants 
(6-MP, azathioprine), looking specifically at the incidence 
of non-Hodgkin’s lymphoma (NHL). They found an overall 
NHL incidence of 6.1 per 10,000 patient-years in patients 
on anti-TNF, which compares to an incidence in the normal 
population of 1.9 per 10,000 patient-years. This significant 
increase in NHL risk becomes less apparent when we com-
pare data by Kandiel et al83 which showed the observed rate 
of NHL in Crohn’s patients on immunomodulators alone 
of 3.6 per 100,000 patient-years. Overall, this suggests a 
modest increase in lymphoma risk in patients on anti-TNF 
therapy. More specific concerns arise about hepato-splenic 
T-cell lymphoma (HSTCL) in young patients on infliximab; 
8 cases have been reported over an 8-year period (1998 to 
2006) to the FDA,84 all of which were fatal. A further 8 IBD 
cases (and 1 RA patient) have since been reported to the FDA 
AER scheme, including 3 cases involving adalimumab.85 
Of note, all 16 cases were being concomitantly treated with 
immunosuppressants, either 6-MP or azathioprine.
A recent alert from the FDA (Aug 4 2009)86 reported an 
increased risk of leukemia in patients treated with anti-TNF 
therapies, reflecting 147 postmarketing reports of leukemia 
in all patients, including adults, using anti-TNF therapy. 
Again, the same article notes that 61% of cases of malignancy 
reported occurred in patients that were concomitantly on 
azathioprine/6-MP or methotrexate.
Anti-TNF therapies have also been implemented in skin 
cancers- one study87 reported an odds ratio of 1.5 (95% CI 1.2 
to 1.8) for nonmelanoma skin cancers. Various malignancies 
were reported in the follow-up period of ACT 1 and ACT 2,54 
including prostate adenocarcinoma (1 patient), basal cell 
carcinoma (2 patients), colonic dysplasia (1 patient), and 
rectal adenocarcinoma (1 patient). Though some of these 
may be incidental findings, long term follow-up studies will 
determine if the association with infliximab is confirmed.
Antibody formation
A concern arises about the formation of antibodies to 
infliximab; described as human anti-chimeric antibodies, or 
ATIs. This has not been studied extensively in UC, though 
studies in Crohn’s disease are helpful; Baert et al88 evaluated 
antibody formation in 125 patients with Crohn’s disease on 
episodic infliximab therapy and assessed patients for side 
effects and loss of effect. Sixty-one percent (76 patients) 
were shown to have detectable antibodies during the study 
period, though notably incidence did not increase with 
repeated infusions. Patients on concomitant immunosup-
pressive therapy (eg, azathioprine) had a lower incidence 
of antibody formation (43%) compared to those not on 
immunosuppressants (75%). The cumulative incidence of 
infusion reactions was 27%, and the occurrence of such a 
reaction strongly correlated with the concentration of anti-
bodies against infliximab. Notably, there was also a clear 
negative relationship between the concentration of antibodies 
against infliximab and the duration of response to infliximab. 
The median duration of response among patients with low 
(8 µg/mL) antibody concentrations was 71 days (95% CI 57 
to 88) compared to those who had a high antibody concentra-
tion (8 µg/mL) who had a median duration of response of 
35 days (95% CI 28 to 42) (P  0.001).
However, more recently, Maser et al89 took the focus 
away from antibody formation and placed more emphasis 
on infliximab trough levels; Maser evaluated antibody for-
mation and trough serum infliximab levels in 105 patients 
with Crohn’s disease who were starting infliximab therapy. 
82/105 (78%) of these were scheduled every 6 to 8 weeks 
as maintenance, whereas 23/105 (22%) were episodic. After 
a median of 14 infusions, 21% of patients had detectable 
antibodies (a further 54% were antibody “inconclusive”). 
Antibody formation was higher among patients undergoing 
episodic therapy (39%) than those undergoing maintenance 
therapy (16%) (P = 0.036) and was associated with a higher 
rate of infusion reactions (50% vs 21%; P = 0.018). How-
ever, the median durations of interval clinical remission 
between infusions were not different between antibody 
positive patients and antibody-negative patients who had 
an undetectable serum infliximab concentration (66% vs 
67%). In contrast, a positive relationship was found between 
the serum concentration of infliximab and both the interval 
clinical remission (R2 = 0.61; P  0.001), and the change 
in endoscopic score from baseline (R2 = 0.46; P  0.001). 
Overall, the rate of clinical remission was higher in patients 
with a detectable infliximab trough level regardless of the 
presence of antibodies to infliximab.
Impact of infliximab on postcolectomy 
complications
Another important issue is whether patients who undergo 
colectomy on infliximab suffer from more postoperative 
complications. This question was addressed in two studies. 
Mor et al90 performed a case-matched retrospective study of 
postoperative complications after restorative proctocolectomy 
(RP) between 2000 and 2006 in UC patients who were 
and were not treated with infliximab. In this time period, 
46 cases were patients on infliximab who underwent a two-
stage RP, who were then compared to infliximab-naive UC Clinical and Experimental Gastroenterology 2009:2 156
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controls who also underwent two-stage RP. Extent of UC and 
inflammatory markers were similar in these groups. Overall 
prevalence of early postoperative complications (eg, sepsis, 
leak, postoperative hemorrhage, ileus, thrombosis) was 
16/46 (35%) in the infliximab group compared to 7/46 (15%) 
in the infliximab-naïve group (P = 0.027). Late postop-
erative complications (eg, pouchitis, stricture, small bowel 
obstruction) occurred in 24/46 (52%) of the infliximab group 
compared to 17/46 (37%) in the infliximab-naïve group 
(P = 0.23).
A similar study91 involving the records of 47 UC patients 
who had received infliximab prior to RP compared to 
254 UC patients who were infliximab-naïve. Surgical mor-
bidity was similar between the groups (62% for infliximab-
treated vs 49% for infliximab-naïve patients, P = 0.1), 
though anastomotic leaks (P = 0.02), pouch-specific disease 
(P = 0.01) and infectious complications (P  0.01) were more 
common in the infliximab group.
These studies raise concerns that giving infliximab may 
increase the risk of post-operative complications. Unfor-
tunately, the retrospective nature of these studies raises 
concerns about selection bias; the infliximab cohort may be 
an inherently sicker group and may have been immunosup-
pressed by concurrent immunosuppressive drugs for a longer 
period of time than the control populations selected.
Other adverse events
Infliximab has been associated with the development or 
worsening of demyelination in some studies. One study 
examining the occurrence of demyelination in patients 
on anti-TNF therapies as reported to the FDA AERS92 
identified 19 cases of demyelination in the arthritides (17 with 
etanercept, 2 with infliximab) – the paper noted that to date 
(2001), 77,152 patients were receiving etanercept, implying 
an incidence of demyelination of 31 per 100,000 patient 
years in etanercept-treated patients, compared to 4 to 6 per 
100,000 per year in the general public. Of note, in follow-
up data from ACT 1 and ACT 2,54 3 neurological events 
occurred, all in infliximab-treated patients; 2 patients devel-
oped optic neuritis, and 1 patient developed a multifocal 
motor neuropathy.
Finally, a randomized, double blind, placebo-controlled 
trial of infliximab in patients with moderate to severe heart 
failure (the ATTACH trial)93 to assess its efficacy in treating 
heart failure actually found it to worsen the clinical condition 
in patients with severe heart failure. Thus, in patients with 
NYHA class III–IV heart failure, infliximab is considered 
relatively contraindicated.
Steps to reduce the risk 
of adverse events
Infusion reactions are relatively uncommon, and infliximab 
infusions are generally well tolerated. If a mild reac-
tion occurs, future infusions can be pre-medicated with 
diphenhydramine and acetaminophen or a non-sedating 
antihistamine.71 In order to reduce the risk of morbidity 
from tuberculosis, patients should be tested for latent TB 
with an intradermal PPD (tuberculin antigen) test.94 Most 
physicians also perform a chest X-ray prior to initiating 
therapy. Also, we test at-risk groups for chronic hepatitis 
B. In addition, all patients should have regular follow-up by 
their gastroenterologist, and receive appropriate vaccinations 
against viral and bacterial infections; the Centers for Disease 
Control recommends an influenza, H1N1, pneumococcus, 
and hepatitis B vaccination in at-risk individuals receiving 
immunosuppression.95,96
Patient-focused perspectives
Adherence
Our understanding of medication adherence in patients 
with UC is mostly based on the use of mesalamine. Kane 
et al97,98 have documented adherence rates in patients with 
UC, and reported that only 40% of patients were found to 
be adherent with mesalamine, and the median amount of 
medication consumed was 71% of the prescribed amount. 
This was primarily attributed to the pill burden of mesalamine 
compounds. Medication non-adherence in UC was shown to 
have a detrimental effect on patient wellbeing, with a 5-fold 
increased risk (61%) of disease relapse compared to those 
who were adherent (11%; P = 0.001).
In contrast, infliximab non-adherence in patients with 
Crohn’s disease has been reported to be as low as 4%, and was 
associated with time since initial infusion and female gender in 
a multi-variate analysis.99 Patient out-of-pocket costs may also 
influence adherence to anti-TNF agents such as infliximab.100 
In patients with RA, infliximab adherence is superior to that 
of methotrexate and sulfasalazine, and similar to that of 
adalimumab.101 Overall, it appears that non-adherence with 
infliximab is not a major issue for patient treatment.
Quality-of-life
Quality of life (QoL) is an important endpoint that mirrors a 
patient’s response to a drug, encompassing both the therapeutic 
effects of the drug, and the side effects created by the drug. 
The QoL model in UC focuses on 3 areas, namely physical 
function (loose stools, rectal bleeding, abdominal pain), Clinical and Experimental Gastroenterology 2009:2 157
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emotional function (anger, embarrassment), and social 
function (absenteeism, effects on social gatherings).102
The impact of UC on patients’ QoL has recently been 
assessed from data derived from the PODIUM study (Pentasa 
Once Daily In UC for Maintenance of Remission)103 using 
the UC-DAI (Ulcerative Colitis Disease Activity Index) as 
a standardized marker. Patients with mild/moderate UC had 
a health-related utility comparable to those with cardiac 
dysrhythmia or gout (mean utility of 0.775 vs 0.774 or 0.771 
respectively). Furthermore, patients with severe relapsing UC 
had a similar utility to those with emphysema or renal failure 
(mean utility of 0.660 vs 0.663 or 0.651 respectively).
QoL related to anti-TNF use in UC patients has been 
addressed in only a small number of the studies discussed 
above. And considering it is a relatively novel therapy in this 
disease, long-term data are limited. To a certain extent, for 
now one must extrapolate from short-term data while indeed 
being mindful of the fact that the very patients in a UC cohort 
that receive infliximab are a sicker cohort of patients. For 
example, the Norwegian IBD cohort study that examined 
immunosuppressive use in UC identified a deterioration in 
QoL,104 though again this may have reflected a selection bias, 
ie, a selection of inherently sicker UC patients.
In the ACT 1 and ACT 2 trials above,54,105 a total of 
728 patients randomized to either infliximab or placebo also 
provided data to assess QoL by way of the Changes in Inflam-
matory Bowel Disease Questionnaire (IBDQ) and Medical 
Outcomes Study 36-Item Short Form Health Survey Physical 
and Mental Component Summary (PCS, MCS). At 8 weeks 
the IBDQ score was significantly higher (better) in both inf-
liximab groups (5 mg/kg, 10 mg/kg) than placebo (40 and 36, 
respectively, compared to 28, P  0.001). This was mirrored 
by equally positive results using the PCS and MCS scores. 
This benefit was sustained throughout the follow-up period 
of 1 year. Notably, patients who achieved remission had QoL 
scores close to population norms. Furthermore, mucosal 
healing inferred a greater QoL benefit than in patients who 
did not demonstrate mucosal healing.
Alternatives to infliximab
In patients with moderate to severe UC, a number of existing 
and novel therapeutic options exist. Azathioprine/6-MP and 
methotrexate are all efficacious in this patient population, 
although robust RCT evidence to support their use is lacking.
Azathioprine, 6-MP, methotrexate
Patients with moderate-severe UC requiring oral steroids, 
or who have failed 5-ASAs, have traditionally been treated 
with azathioprine/6-MP to maintain remission. The data to 
support this strategy is weak, as results from controlled trials 
have reported conflicting results, and only enrolled patients 
with severe or steroid-dependent disease.106 A meta-analysis 
of 6 of these studies concluded that azathioprine was superior 
to placebo for maintenance of remission in UC.107 Similarly, 
the only RCT to examine methotrexate in this setting showed 
no benefits, despite efficacy in open-label studies.108,109
Cyclosporine
Cyclosporine, on the other hand, has clear short-term efficacy 
in patients with severe or steroid-refractory UC. Lichtiger 
et al110 conducted a small placebo-controlled trial that pro-
vided evidence in support of cyclosporine use in acute severe 
UC; 9 of 11(82%) patients with severe steroid-refractory UC 
randomized to iv cyclosporine responded, whereas none of 
the placebo group improved. Other studies have also reported 
short term response rates of 85% and 86% in steroid-refrac-
tory patients with UC.111,112 Despite these high initial response 
rates, one of the limitations in cyclosporine’s use has been the 
variable long-term colectomy rates. In Cohen et al’s112 study 
of steroid-refractory UC, 72% of cyclosporine-responders 
avoided colectomy after a median 5.5 years follow-up, 
particularly if they transitioned to azathioprine/6-MP (80% 
colectomy-free). In contrast, other studies have reported that 
up to 88% of patients required colectomy within 7 years of 
being treated with cyclosporine.113 The cumulative data sug-
gest that cyclosporine is an effective option in patients with 
steroid-refractory UC who are naïve to azathioprine/6-MP 
and can thus transition to these agents to enhance its long-
term colectomy-sparing effects.
The other disadvantage of using cyclosporine is its 
side-effects, which limit long-term use. These include renal 
impairment, hypertension, tremor, seizures and infections. 
Sternthal et al114 reviewed the records of 111 patients treated 
with cyclosporine for IBD over a mean treatment duration 
of 9 months; nephrotoxicitiy occurred in 5% and serious 
infections in 6%. Seizures, anaphylaxis and 2 deaths were 
also reported. Minor events included paresthesias in 51%, 
hypomagnesemia in 42%, hypertension in 39%, hypertricho-
sis in 27% and abnormal liver tests in 19%.
Other agents
Other anti-TNF agents under investigation for moderate to 
severe UC include adalimumab, certolizumab and golimumab. 
In patients with steroid-refractory disease, the efficacy of both 
basiliximab and visilizumab were disappointing in initial trials, 
and other agents have been examined only anecdotally.115Clinical and Experimental Gastroenterology 2009:2 158
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Finally, colectomy and end-ileostomy, or ileal pouch anal 
anastomosis (IPAA) always remain an option for patients 
with severe disease who have failed conventional therapies. 
A colectomy removes the risk of colon cancer, and the need 
for maintenance medications. Most patients can expect 
6 to 8 stools per day with a successful IPAA. Pouchitis is the 
most commonly occurring long-term complication of IPAA, 
and occurs in 20% to 50% of patients over the life of 
the pouch.116–119
Conclusions
In patients with moderate to severe UC, infliximab is an 
effective therapy which provides an additional therapeutic 
option for these patients. Those patients with moderate 
disease who do not require hospitalization or iv steroids 
now have the options of treatment with either infliximab, 
or oral steroids as a bridge to azathioprine/6-MP. There 
appears to be a modest reduction in the risk of colectomy 
from infliximab over 1 year in patients with moderate 
to severe disease, but the overall colectomy rate is low 
(10% to 17%). Whether concomitant azathioprine/6-MP 
improves long-term outcomes with infliximab in UC is 
unknown; the colectomy rates in ACT 1 and ACT 2 were 
independent of azathioprine/6-MP use over 1 year. A UC 
equivalent of the SONIC trial would be required to address 
these questions.120
In patients with severe, or steroid-refractory UC, there 
are insufficient data to conclude whether iv infliximab or iv 
cyclosporine is the best approach. Cyclosporine is associ-
ated with higher initial response rates than infliximab, and 
at earlier time-points; 82% response within 7 days with 
cyclosporine, compared with 50% response at 2 weeks 
with infliximab.48,110 The long-term colectomy-sparing rates 
with cyclosporine are often criticized, but if one looks at the 
sparse data in similar populations treated with infliximab, 
they are not that different. Within 2 years, 46% of patients 
treated with infliximab in the Jarnerot study had under-
gone a colectomy, compared with a 51% colectomy rate in 
Lichtiger’s cohort treated with cyclosporine.51,121 Only an 
ongoing direct comparison randomized controlled trial will 
answer this critical question. Our personal practice is to use 
cyclosporine in steroid-refractory patients with UC who 
are azathioprine/6-MP-naïve, and reserve infliximab for 
those who have already failed azathioprine/6-MP, or have 
contra-indications to cyclosporine. When steroid-refractory 
patients fail infliximab, we feel the small amount of data 
published to date suggest that the modest benefits gained 
by adding cyclosporine need to be considered in light of 
the higher initial risk of serious adverse events of “triple” 
immunosuppression.
It appears likely that expanded use of infliximab may lead 
to more patients with severe disease retaining their colon for 
longer periods of their lives. This advantage will require an 
increased vigilance for dysplasia and cancer development 
during follow-up.122
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